Novo Nordisk
NVO
Performance
About Novo Nordisk
Novo Nordisk is a global healthcare company headquartered in Denmark, founded in 1923. The company specializes in medicines and therapies for diabetes and other serious chronic diseases, with a broad focus on long-term care and disease management. It operates internationally, developing treatments across disease areas including obesity and metabolic disorders, and emphasizes sustainable business practices and patient-centric care.
Recent News
Jobs Day, Semiconductor Earnings, and Stock Market Momentum: What to Watch This Week
As Millions Lose Weight on GLP-1s, They're Starting to Turn to Retailers to Refresh Their Wardrobes
Lilly’s Foundayo Reaches 1,390 Patients in First Week, Trailing Novo’s Oral Wegovy Launch
Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder
Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals?
Amazon Launches GLP‑1 Weight‑Loss Program, Targeting $25‑Per‑Month Market
The 2026 Agencies Vanguard Awards: Defying the Odds to Make Work That Resonates
5 FDA Decisions to Watch in the First Quarter of 2026
Medicare Launches $50 GLP‑1 Bridge Pilot for Weight‑Loss Drugs
Telehealth Provider Hims Goes After Novo's Weight Loss Pill with Compounded Version
Trump's Obesity Drug Plan for Medicare Would Cost Insurers Billions
STAT+: Novo Nordisk’s Less-Bad News on Its Wegovy Pill Boosts Earnings and Share Price
Biotech in 2025: A Retrospective
FDA Approves Eli Lilly’s Foundayo, Pitting First Oral Obesity Pill Against Novo Nordisk’s Wegovy
Thursday Links: A Job in a System
High-Dose Wegovy Debuts at $399 for Self-Paying Patients
STAT+: Finally Cracking KRAS as a Druggable Target
Novo's Double Departures: As GLP-1 Luminary Retires, an Obesity Leader Goes to Boehringer Ingelheim
Lilly’s Obesity Pill Approval Kicks Off New Front in Weight-Loss Drug Wars
European Regulators Approve First‑In‑Human GLP‑1 Gene Therapy Trial for Fractyl Health
Pharma.Aero Studies Geopolitical Instability in the Gulf
Apotex and Orbicular Secure First FDA Tentative Approval for Generic Ozempic
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4
White House Adds Generic Drugs to Direct-to-Consumer TrumpRx Site
Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B
GLP-1s and Anhedonia: The Death of Dopamine Snacking
World Hemophilia Day 2026: New Treatment Era and Improving Diagnosis
UK Researchers Develop Tool to Identify People Most at Risk of Obesity-Related Diseases
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
FDA Proposes Excluding Novo, Lilly Weight Loss Drugs From Bulk Compounding List in Win for the Companies
Novo Nordisk Reports New STEP UP Trial Analyses on Wegovy 7.2mg for Weight Loss
#JPM26: Novo Nordisk CEO Says Pharma Can Learn From the GLP-1 Compounding Boom
FDA Seeks More Cardiovascular Data on Eli Lilly’s Orforglipron After Safety Concerns
Pfizer Searches for Novel Tumor-Selective Antigens With $865M+ Cartography Pact
Semaglutide Race: Torrent Grabs 38% Market Share
Eli Lilly’s Retatrutide Targets Novo Nordisk’s GLP‑1 Stronghold with 28.7% Weight Loss Data
Lilly CEO Sees Weight-Loss Drugs Reaching About Half of Potential Users at Peak
Viking Therapeutics Targets 170% Upside as Dual-Agonist Obesity Drug Shows 14.7% Weight Loss
Canada First in G7 to Approve Generic Ozempic
Vercel COO Discusses How AI Will Bolster Human Interactions in Sales
Ozempic Gains First Australian Approval for Heart‑Disease Treatment
Qualcomm Downgraded, Rivian Upgraded: Wall Street's Top Analyst Calls
USP Adds Tamiflu, Trulicity to Vulnerable List as Upstream Analysis Reshapes Supply Concerns
The Next Generation of GLP-1 Drugs: And How They’ll Reshape Food and Beverage Again
GLP-1 Microdosing May Provide More ‘Tailored Approach to Care’
Amgen Launches Late-Stage Obesity Trial in Patients Who Switch From Rival Drugs
Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users
Structure Therapeutics Reports More Phase 2 Data for Oral GLP-1
Denmark's Q1 GDP Jumps 1.9% YoY, Boosting Nordic Euro‑Stock Rally
JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer
Recent Deals
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy
Cellular Intelligence Secures Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program and Receives Equity Investment
Novo Nordisk Invests in Aspect Biosystems, Expands Partnership to Transfer Cell‑therapy Technologies
Quantonation Ventures Closes €220M Quantum Fund Backed by Toshiba, Novo Holdings and Others
Ray Therapeutics Closes $125M Series B to Advance Vision‑Restoring Therapies